MoonLake Immunotherapeutics Investor Relations Material

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for inflammatory diseases. The company is advancing Sonelokimab, a novel investigational Nanobody, to address conditions such as hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis. MoonLake Immunotherapeutics aims to leverage the therapeutic potential of Sonelokimab to meet significant unmet medical needs in the treatment of these diseases. MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and its shares are listed on the NASDAQ.